Traversa Inks Deal to Evaluate siRNA Delivery Technology with Sanofi-Aventis
March 25, 2010
Traversa Inks Deal to Evaluate siRNA Delivery Technology with Sanofi-Aventis
Under the agreement, the companies will examine the ability of the PTD-DRBD technology to deliver siRNAs against undisclosed targets, with an eye toward developing RNAi therapeutics.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Undisclosed Pharma to Evaluate Silence siRNA-Delivery Technology
September 29, 2011 / Gene Silencing News - Sirnaomics Inks Ocular Disease Drug Deal with Chinese Drugmaker
June 30, 2011 / Gene Silencing News - Amid Delivery Tech Dispute, Alnylam Forges Collaboration with Precision NanoSystems
April 21, 2011 / Gene Silencing News - Sirnaomics Partners with Chinese Pharma on Wound-Healing Drug
December 2, 2010 / Gene Silencing News - EGEN Aims to Use 'Bottom-Up' Approach for RNAi Drug-Development Programs
August 5, 2010 / Gene Silencing News